- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
TRAW
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Traws Pharma Inc · Healthcare · Biotechnology
Latest close
0.45 USD
-7.8%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -69.3% below the Trend Line and sits at 0.7% of its 52-week range. The latest completed week returned -7.8%, after a -41.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.
Setup score
13
out of 100
Latest Close
0.45 USD
31 Jul 2026
1W Return
-7.8%
latest completed week
4W Return
-41.4%
short-term follow-through
12W Return
-79.4%
quarterly tape
Trend Breadth
21.2%
11 of 52 weeks active
Volume Ratio
0.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-7.8%
Latest completed week; four-week move -41.4%.
Indicator stack
12/30
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 38.52%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
49/100
60 relevant articles in the latest sentiment read.
Event risk
11d
Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -69.3% below the Trend Line and sits at 0.7% of its 52-week range. The latest completed week returned -7.8%, after a -41.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.0x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1712-week average 0.17
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.17Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -41.4% over four weeks, -79.4% over 12 weeks, and -69.2% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year11
Trend breadth21.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.11Latest activity-pressure read.
Pressure change-2.6%Four-week change in activity pressure.
Leadership-76.14Latest relative-leadership reading.
RS change-21.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 73%
Model confidence 70%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength33/100Blend of value, momentum, and quality. Underlying universe rank 68; rank 1 is best.
Value42/100Relative valuation strength. Underlying universe rank 59; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum43/100Medium-term price momentum. Underlying universe rank 58; rank 1 is best.
Growth43/100Revenue and earnings growth. Underlying universe rank 58; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 2.7x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -296.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 100.0% Gross profit retained from each unit of revenue.
- Operating margin
- -703.2% Operating profit retained from revenue.
- Free-cash-flow margin
- -456.6% Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -99.0% Net share repurchases relative to market value.
- Shareholder yield
- -99.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment49/100
Weighted news tone is neutral across 60 relevant articles.
6 positive · 45 neutral · 9 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-86.2%Distance below the 52-week high.
13-week volatility18.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher5 of 2621 weeks finished lower.
Best week+46.3%Week of 8 May.
Worst week-33.6%Week of 19 Jun.
Latest week-7.8%Week of 31 Jul.
Shape of recent returns
Strong gains4
Modest gains1
Flat weeks0
Modest losses5
Sharp losses16
Recent vol18.2%13-week weekly-return volatility.
Base vol18.0%52-week weekly-return volatility.
Up/down split20/32Count of positive and negative weeks in the 52-week window.
Average skew16.5% / -11.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape15/100
Trend, activity pressure, participation, and risk combine to a 15/100 tape read.
Indicator analysis17/100Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.
Activity pressure 0.17; No reversal markers Next-Week ExpectancyNegative 38.52%Next-week expectancy is negative with a 38.52% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors38/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 100 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment49/100Weighted news tone is neutral across 60 relevant articles.
TRAW|Traws Pharma Inc|Price:0.486|Chg%:-0.027 Insiders50/100No recent insider transaction evidence is stored.
Earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 0.45 USD | -7.8% | 1.47 USD | 7.77 USD | -1.11 | -76.14 | 516.6K | Off |
| 24 Jul 2026 | 0.49 USD | -27.3% | 1.50 USD | 7.93 USD | -1.14 | -74.34 | 734.8K | Off |
| 17 Jul 2026 | 0.67 USD | -11.7% | 1.52 USD | 8.09 USD | -1.19 | -65.78 | 591.9K | Off |
| 10 Jul 2026 | 0.76 USD | -1.0% | 1.54 USD | 8.25 USD | -1.23 | -63.33 | 898.6K | Off |
| 3 Jul 2026 | 0.77 USD | -7.2% | 1.59 USD | 8.43 USD | -1.08 | -62.72 | 1.0M | Off |
| 26 Jun 2026 | 0.83 USD | -2.7% | 1.64 USD | 8.60 USD | -0.86 | -59.90 | 847.7K | Off |
| 19 Jun 2026 | 0.85 USD | -33.6% | 1.71 USD | 8.78 USD | -0.56 | -61.00 | 6.9M | Off |
| 12 Jun 2026 | 1.28 USD | -6.6% | 1.75 USD | 8.95 USD | -0.27 | -40.51 | 1.8M | Off |
| 5 Jun 2026 | 1.37 USD | -6.2% | 1.78 USD | 9.14 USD | 0.02 | -35.46 | 1.4M | Off |
| 29 May 2026 | 1.46 USD | -2.0% | 1.80 USD | 9.31 USD | 0.32 | -34.81 | 2.7M | Off |
| 22 May 2026 | 1.49 USD | -20.7% | 1.84 USD | 9.49 USD | 0.18 | -31.87 | 3.9M | Off |
| 15 May 2026 | 1.88 USD | -13.8% | 1.88 USD | 9.66 USD | -0.09 | -13.27 | 32.7M | Off |
| 8 May 2026 | 2.18 USD | 46.3% | 1.91 USD | 9.83 USD | -0.35 | 0.47 | 89.9M | Off |
| 1 May 2026 | 1.49 USD | 28.4% | 1.94 USD | 10.02 USD | -0.62 | -27.40 | 1.5M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.